



## XpresSpa Group Has Begun Construction of New XpresCheck™ COVID-19 Pop-Up Testing Facility at Denver International Airport

12/07/20

*Expected to Commence Operations by mid-December*

DENVER, Dec. 07, 2020 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) ("XpresSpa" or the "Company"), a health and wellness company, today announced that it has begun construction of an XpresCheck™ COVID-19 testing facility at Denver International Airport that is expected to be fully operational by mid-December.

XpresCheck is currently building a pop-up facility in the now closed Brookstone location at Concourse B, post-security. This facility will host six separate testing rooms with an anticipated capacity to administer over 400 tests per day. COVID-19 testing options will include the Rapid Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR) Test.

Doug Satzman, XpresSpa CEO, stated, "As cases continue to rise in Colorado and throughout the country, we are pleased to launch XpresCheck at Denver International Airport, which will be our first pop-up location and fifth COVID-19 testing facility across the country. This new pop-up building methodology will enable us to accelerate our rollout to additional airports at a lower cost than our original modular constructed facilities at JFK, Newark, and Logan airports. While our current focus is providing convenient, reliable COVID-19 testing and related medical services, our long-term goal is to become the leading provider in the travel, health and wellness category by helping people manage medical conditions as they pass through the largest U.S. airports."

### **About XpresSpa Group, Inc.**

XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company. XpresSpa Group's core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products, with 50 locations in 25 airports globally. Through its XpresTest, Inc. subsidiary, the Company also provides COVID-19 screening and testing, rapid testing services for other communicable diseases that include influenza, mononucleosis and group A streptococcus, and flu vaccination services under its XpresCheck™ brand. Current XpresCheck Wellness Centers include JFK International Airport, Newark Liberty International Airport, Logan International Airport, and Phoenix Sky Harbor International Airport. To learn more about XpresSpa Group, visit: [www.XpresSpaGroup.com](http://www.XpresSpaGroup.com). To learn more about XpresSpa, visit [www.XpresSpa.com](http://www.XpresSpa.com). To learn more about XpresCheck, visit [www.XpresCheck.com](http://www.XpresCheck.com).

### **About Denver International Airport**

Denver International Airport is the fifth-busiest airport in the United States, with more than 69 million passengers traveling through the airport in 2019. DEN is the primary economic engine for the state of Colorado, generating more than \$33 billion for the region annually. For more information visit [www.FlyDenver.com](http://www.FlyDenver.com).

### **Forward-Looking Statements**

This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of a COVID-19 vaccination when it becomes available (including whether such vaccination becomes available in the near term), the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability further expand our initial sites, and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group's most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.

### **Investor Relations:**

ICR  
Raphael Gross

[ir@xpresspagroup.com](mailto:ir@xpresspagroup.com)  
(203) 682-8253

**Media:**

Julie Ferguson

[Julie@ifprmedia.com](mailto:Julie@ifprmedia.com)

(312) 385-0098

**XpresSpa** Group

Source: XpresSpa Group, Inc.